Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pulmonary Arterial Hypertension
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a multi-national, multi-center, prospective, non-randomized, open label trial of patients implanted with the study device. A total of 20 patients will be implanted with the study device and followed at regular intervals for 1 year and then annually for a total of 5 years post implant.
This is a multi-national, multi-center, prospective, non-randomized, open label trial of patients implanted with the study device. A total of 20 patients will be implanted with the study device and followed at regular intervals for 1 year and then annually for a total of 5 years post implant.
Tracking Information
- NCT #
- NCT03838445
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Victor Tapson, M.D. Cedars-Sinai Medical Center